ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising th...

Full description

Saved in:
Bibliographic Details
Main Authors BELLOTTO, Manolo, BARRIL ALONSO, Xavier, GARCIA COLLAZO, Ana Maria, CUBERO JORDA, Elena
Format Patent
LanguageEnglish
French
Published 03.06.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease. La présente invention concerne des composés de formule (IA) et (IB), (IA) et (IB), et leurs sels et solvates, dans les formules, R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, et G sont tels que définis dans la spécification, ainsi que des procédés pour leur préparation, des compositions pharmaceutiques les comprenant, et leur utilisation pour le traitement et/ou la prévention, par exemple, de maladies de stockage lysosomal, telles que la maladie de Krabbe, et les α-synucléinopathies, telles que la maladie de Parkinson.
Bibliography:Application Number: WO2020IB61156